Skin Biopsy Market Report 2025

The skin biopsy market size has grown strongly in recent years. It will grow from $1.72 billion in 2024 to $1.86 billion in 2025 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period is attributed to the rising prevalence of skin cancer and chronic skin disorders, growing awareness of early disease detection, adoption of punch biopsy as a standard diagnostic tool, expansion of hospital and clinic infrastructure, and supportive government initiatives for cancer screening programs.

The skin biopsy market size is expected to see strong growth in the next few years. It will grow to $2.54 billion in 2029 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period is driven by increasing demand for minimally invasive diagnostic procedures, integration of artificial intelligence in biopsy analysis, a rising geriatric population susceptible to dermatological conditions, healthcare investments in emerging economies, and growth in teledermatology and remote consultation services. Key trends in the forecast period include the adoption of digital pathology platforms, use of non-invasive alternatives such as liquid biopsy, personalized treatment planning based on biopsy results, collaborations between device manufacturers and healthcare providers, and development of portable, patient-friendly biopsy devices.

The increasing prevalence of skin disorders is expected to drive growth in the skin biopsy market. Skin disorders encompass a broad spectrum of conditions that affect the skin’s function, structure, or appearance, often presenting with symptoms such as irritation, inflammation, or abnormal tissue growth. These conditions include acne, eczema, psoriasis, dermatitis, vitiligo, fungal infections, warts, and skin cancer. A significant contributor to the rise in skin disorders is growing exposure to environmental pollutants, which can compromise the skin barrier and trigger allergic or inflammatory responses. Skin biopsy supports the diagnosis of these disorders by providing accurate tissue samples for microscopic analysis, which facilitates early identification of infections, inflammatory conditions, and skin cancers. For example, in 2023, Cancer Australia, a government agency, reported around eight thousand two hundred fifty-seven new melanoma cases, accounting for two point six percent of all cancer-related deaths in the country. As a result, the increasing rate of skin disorders is contributing to the expansion of the skin biopsy market.

The rise in healthcare expenditure is also expected to contribute to the growth of the skin biopsy market. Healthcare expenditure refers to the total financial resources allocated to medical services, treatments, infrastructure, research, and public health programs aimed at improving health outcomes. A key reason for this increase is the growing number of chronic health conditions, which often require long-term care and costly interventions. Greater investment in healthcare leads to broader access to advanced diagnostic tools and expanded dermatological services. This supports early and accurate diagnosis of skin conditions and enhances patient care and overall health system performance. For instance, in May 2024, the Office for National Statistics, a government organization in the United Kingdom, reported a five point six percent increase in healthcare spending during 2023, compared to a zero point nine percent increase in the prior year. Consequently, the growth in healthcare expenditure is playing a significant role in the development of the skin biopsy market.

Leading companies within the skin biopsy market are focusing on the development of advanced technologies, such as automated biopsy systems, to improve diagnostic precision, procedural speed, patient experience, and sample quality. These systems use powered mechanisms instead of manual tools to collect tissue samples with higher accuracy and consistency, which helps reduce operator error and discomfort for patients. For example, in May 2023, Argon Medical Devices Inc., a medical device manufacturer based in the United States, introduced the SuperCore Advantage Semi-Automatic Biopsy Instrument. This device is designed with ergonomic features and advanced needle technology to enhance precision during tissue collection. It offers a specialized needle tip for cleaner samples and a smooth-firing system to improve user control and procedural efficiency.

Major players in the skin biopsy market are Olympus Corporation, Sysmex Corporation, Bio-Rad Laboratories, Exact Sciences Corporation, Cardinal Health Inc., Merit Medical Systems Inc., Abbott Laboratories, Danaher Corporation, Philips Healthcare, Becton, Dickinson and Company (BD), Hologic Inc., Cook Medical, Leica Biosystems Nussloch GmbH, AccuTec Inc., MedicalExpo brands, Delasco, Paramount Surgimed Ltd., Neoteryx, Innovia Medical, and World Precision Instruments.

North America was the largest region in the skin biopsy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in skin biopsy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the skin biopsy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers’ margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

A skin biopsy is a medical procedure in which a small sample of skin tissue is removed for diagnostic or research purposes. It is used to diagnose skin conditions, including infections, inflammatory disorders, and skin cancers, by examining the cellular structure of the tissue. This procedure helps clinicians determine the nature, severity, and appropriate treatment for various skin abnormalities.

The primary types of skin biopsy are excisional biopsy, incisional biopsy, punch biopsy, shave biopsy, and needle biopsy. Excisional biopsy involves surgically removing an entire lump, lesion, or suspicious tissue area along with a margin of normal surrounding tissue for microscopic examination. Procedure types include surgical biopsy, image-guided biopsy, dermatoscopic biopsy, and endoscopic biopsy. Applications include dermatology, oncology, pathology, clinical research, and cosmetic procedures. Key end-users include hospitals, ambulatory surgical centers (ASCs), diagnostic laboratories, research institutions, and dermatology clinics.

The skin biopsy market research report is one of a series of new reports that provides skin biopsy market statistics, including skin biopsy industry global market size, regional shares, competitors with a skin biopsy market share, detailed skin biopsy market segments, market trends and opportunities, and any further data you may need to thrive in the skin biopsy industry. This skin biopsy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The skin biopsy market includes revenues earned by entities through skin tissue collection procedures, histopathological examination, molecular and immunohistochemistry testing, diagnostic pathology reporting services, and follow-up consultation services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.